GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B6994 L-692,585Summary: ghrelin receptor (GHS-R1a) agonist
- B6999 FPL 55712Summary: Leukotriene receptor antagonist
- B7000 2'-MeCCPASummary: A1 adenosine receptor agonist
- B7002 O-1918Summary: endothelial anandamide receptor antagonist
- B7004 (±)-Cloprostenol sodium saltSummary: prostaglandin F2α (PGF2α) analog,FP receptor agonist
- B7005 Prostaglandin E2Target: Prostaglandin EP receptorsSummary: Endogenous prostaglandin
- B7011 Leukotriene B4Summary: BLT1/BLT2 receptor agonist
- B7013 SR 49059Summary: vasopressin V1A receptor antagonist
- B7023 MK-571Target: Leukotriene and Related ReceptorsSummary: leukotriene D4 receptor antagonist, orally active
- B7038 JTE 013Summary: S1P receptor antagonist